Elevance Health (ELV) Stock Forecast & Price Target

Compare

2,864 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELV Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$389.07

▲(12.37% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $389.07 with a high forecast of $425.00 and a low forecast of $332.00. The average price target represents a 12.37% change from the last price of $346.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"270":"$270","427":"$427","309.25":"$309.3","348.5":"$348.5","387.75":"$387.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$425.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":389.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$389.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$332.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[270,309.25,348.5,387.75,427],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,341.83,348.2276923076923,354.6253846153846,361.0230769230769,367.4207692307692,373.8184615384615,380.2161538461538,386.61384615384617,393.01153846153846,399.40923076923076,405.80692307692306,412.2046153846154,418.6023076923077,{"y":425,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,341.83,345.46384615384613,349.0976923076923,352.73153846153843,356.3653846153846,359.99923076923073,363.63307692307694,367.2669230769231,370.90076923076924,374.5346153846154,378.16846153846154,381.8023076923077,385.43615384615384,{"y":389.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,341.83,341.07384615384615,340.3176923076923,339.5615384615385,338.8053846153846,338.04923076923075,337.2930769230769,336.5369230769231,335.78076923076924,335.0246153846154,334.2684615384615,333.5123076923077,332.75615384615384,{"y":332,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":388.188,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.345,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.246,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.238,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.443,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.593,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.768,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.295,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.954,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.573,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.989,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":350.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$425.00

Average Price Target$389.07

Lowest Price Target$332.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ben Hendrix

RBC Capital

$392→$358

Hold

3.40%

Upside

Downgraded

02/03/26

Elevance Health downgraded to Sector Perform from Outperform at RBC CapitalElevance Health downgraded to Sector Perform from Outperform at RBC Capital

David S Macdonald

Truist Financial

$400→$390

Buy

12.64%

Upside

Reiterated

02/02/26

Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)

Lisa Gill

J.P. Morgan

$394→$397

Buy

14.66%

Upside

Reiterated

02/02/26

Elevance Health price target raised to $397 from $394 at JPMorganElevance Health price target raised to $397 from $394 at JPMorgan

Lance Wilkes

Bernstein

$431→$409

Buy

18.13%

Upside

Reiterated

02/02/26

Elevance Health (ELV) Receives a Buy from Bernstein

Ryan Langston

TD Cowen

$400

Buy

15.53%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

$424→$391

Buy

12.93%

Upside

Reiterated

01/30/26

Elevance Health price target lowered to $391 from $424 at Wells FargoElevance Health price target lowered to $391 from $424 at Wells Fargo

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$395

Buy

14.08%

Upside

Reiterated

01/30/26

Jefferies Remains a Buy on Elevance Health (ELV)

Erin Wright

Morgan Stanley

$352

Hold

1.66%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)

A.J. Rice

UBS

$425→$400

Buy

15.53%

Upside

Reiterated

01/29/26

Elevance Health price target lowered to $400 from $425 at UBSElevance Health price target lowered to $400 from $425 at UBS

George Hill

Deutsche Bank

$320→$332

Hold

-4.11%

Downside

Reiterated

01/29/26

Elevance Health price target raised to $332 from $320 at Deutsche BankElevance Health price target raised to $332 from $320 at Deutsche Bank

Kevin Fischbeck

Bank of America Securities

$385

Hold

11.19%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS), Elevance Health (NYSE: ELV) and Universal Health (NYSE: UHS)

Andrew Mok CFA

Barclays

$404→$393

Buy

13.51%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), HCA Healthcare (HCA)

Jason Cassorla

Guggenheim

$414→$396

Buy

14.37%

Upside

Reiterated

01/28/26

Elevance Health price target lowered to $396 from $414 at GuggenheimElevance Health price target lowered to $396 from $414 at Guggenheim

Ann Hynes

Mizuho Securities

$413

Buy

19.28%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV) and Penumbra (NYSE: PEN)

Justin Lake

Wolfe Research

$425

Buy

22.75%

Upside

Upgraded

01/07/26

Elevance Health upgraded to Outperform from Peer Perform at Wolfe ResearchElevance Health upgraded to Outperform from Peer Perform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ben Hendrix

RBC Capital

$392→$358

Hold

3.40%

Upside

Downgraded

02/03/26

Elevance Health downgraded to Sector Perform from Outperform at RBC CapitalElevance Health downgraded to Sector Perform from Outperform at RBC Capital

David S Macdonald

Truist Financial

$400→$390

Buy

12.64%

Upside

Reiterated

02/02/26

Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)

Lisa Gill

J.P. Morgan

$394→$397

Buy

14.66%

Upside

Reiterated

02/02/26

Elevance Health price target raised to $397 from $394 at JPMorganElevance Health price target raised to $397 from $394 at JPMorgan

Lance Wilkes

Bernstein

$431→$409

Buy

18.13%

Upside

Reiterated

02/02/26

Elevance Health (ELV) Receives a Buy from Bernstein

Ryan Langston

TD Cowen

$400

Buy

15.53%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Elevance Health (NYSE: ELV)

Stephen Baxter

Wells Fargo

$424→$391

Buy

12.93%

Upside

Reiterated

01/30/26

Elevance Health price target lowered to $391 from $424 at Wells FargoElevance Health price target lowered to $391 from $424 at Wells Fargo

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$395

Buy

14.08%

Upside

Reiterated

01/30/26

Jefferies Remains a Buy on Elevance Health (ELV)

Erin Wright

Morgan Stanley

$352

Hold

1.66%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)

A.J. Rice

UBS

$425→$400

Buy

15.53%

Upside

Reiterated

01/29/26

Elevance Health price target lowered to $400 from $425 at UBSElevance Health price target lowered to $400 from $425 at UBS

George Hill

Deutsche Bank

$320→$332

Hold

-4.11%

Downside

Reiterated

01/29/26

Elevance Health price target raised to $332 from $320 at Deutsche BankElevance Health price target raised to $332 from $320 at Deutsche Bank

Kevin Fischbeck

Bank of America Securities

$385

Hold

11.19%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS), Elevance Health (NYSE: ELV) and Universal Health (NYSE: UHS)

Andrew Mok CFA

Barclays

$404→$393

Buy

13.51%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), HCA Healthcare (HCA)

Jason Cassorla

Guggenheim

$414→$396

Buy

14.37%

Upside

Reiterated

01/28/26

Elevance Health price target lowered to $396 from $414 at GuggenheimElevance Health price target lowered to $396 from $414 at Guggenheim

Ann Hynes

Mizuho Securities

$413

Buy

19.28%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV) and Penumbra (NYSE: PEN)

Justin Lake

Wolfe Research

$425

Buy

22.75%

Upside

Upgraded

01/07/26

Elevance Health upgraded to Outperform from Peer Perform at Wolfe ResearchElevance Health upgraded to Outperform from Peer Perform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+2.04%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.04% per trade.

1 Year

A.J. RiceUBS

Success Rate

21/31 ratings generated profit

Average Return

+15.85%

reiterated a buy rating 22 days ago

Copying A.J. Rice's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +15.85% per trade.

2 Years

xxx

Success Rate

25/31 ratings generated profit

Average Return

+37.70%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.65% of your transactions generating a profit, with an average return of +37.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELV has received 28 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 389.07.

Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $10.58 with a range of $6.53 to $11.53. The previous quarter’s EPS was $3.33. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.77B with a range of $45.78B to $51.83B. The previous quarter’s sales results were $49.75B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health, Inc.’s 12-month average price target is 389.07.

What is ELV’s upside potential, based on the analysts’ average price target?

Elevance Health, Inc. has 12.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELV a Buy, Sell or Hold?

Elevance Health, Inc. has a consensus rating of Moderate Buy which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is Elevance Health, Inc.’s price target?

The average price target for Elevance Health, Inc. is 389.07. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $425.00 ,the lowest forecast is $332.00. The average price target represents 12.37% Increase from the current price of $346.24.

What do analysts say about Elevance Health, Inc.?

Elevance Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ELV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Elevance Health (ELV) Stock Forecast & Price Target

ELV Analyst Ratings

ELV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

ELV Analyst Recommendation Trends

ELV Financial Forecast

ELV Earnings Forecast

ELV Sales Forecast

ELV Stock Forecast FAQ

Detailed List of Analyst Forecasts